Phaseline

Companies › Polaris Group

Polaris Group: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Gastroenterology, Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ADI-PEG 20
Argininosuccinate synthase 1 (ASS1) depletion via pegylated arginine deiminase
ASS1Phase 3Hepatocellular Carcinoma; Glioblastoma Multiforme (GBM); Nonalcoholic Steatohepatitis (NASH); Prostate CancerFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04587830ADI-PEG 20Phase 2Glioblastoma Multiforme (GBM)OncologyFeb 2027
NCT06085729ADI-PEG 20Phase 1Prostate CancerOncologySep 2027
NCT05842512ADI-PEG 20Phase 2Nonalcoholic Steatohepatitis (NASH)GastroenterologyDec 2027
NCT05317819ADI-PEG 20Phase 3Hepatocellular CarcinomaOncologySep 2028

From the company's SEC filings

Cash of $302m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Targets

ASS1 (1)

Companies with the same targets

–

Companies built like this

Corcept Therapeutics Colgate Palmolive Puma Biotechnology Phathom Pharmaceuticals LaNova Medicines Zhejiang

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.